245 related articles for article (PubMed ID: 30357484)
1. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.
Hayakawa M; Izumi K; Higashida-Konishi M; Ushikubo M; Tsukamoto M; Akiya K; Araki K; Oshima H
Rheumatol Int; 2019 Jan; 39(1):161-166. PubMed ID: 30357484
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis.
Palmou-Fontana N; Sánchez Gaviño JA; McGonagle D; García-Martinez E; Iñiguez de Onzoño Martín L
Dermatology; 2014; 228(4):311-3. PubMed ID: 24942661
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
[TBL] [Abstract][Full Text] [Related]
4. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
5. [Psoriasis-like eruption induced by adalimumab in a patient with rheumatoid arthritis : a case report and review of literature].
Kuno H; Kotani T; Takeuchi T; Wakura D; Wakura R; Yu A; Makino S; Moriwaki S; Hanafusa T
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(6):520-5. PubMed ID: 23291487
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
Kondo N; Fujisawa J; Endo N
Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
[TBL] [Abstract][Full Text] [Related]
7. [Erysipelas without fever or biologic inflammation during tocilizumab therapy].
Yéléhé-Okouma M; Henry J; Petitpain N; Schmutz JL; Gillet P
Ann Dermatol Venereol; 2017; 144(6-7):434-437. PubMed ID: 28396064
[TBL] [Abstract][Full Text] [Related]
8. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
[No Abstract] [Full Text] [Related]
10. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.
Mori S; Yoshitama T; Abe Y; Hidaka T; Hirakata N; Aoyagi K; Ueki Y
Rheumatology (Oxford); 2019 Jul; 58(7):1274-1284. PubMed ID: 30793749
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.
Saiki O; Uda H
Rheumatol Int; 2018 Dec; 38(12):2307-2313. PubMed ID: 30206670
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
Abdulkader OAF; Qushmaq K; Aljishi F
Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
[TBL] [Abstract][Full Text] [Related]
13. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
Kivitz A; Olech E; Borofsky MA; Zazueta B; Navarro-Sarabia F; Radominski SC; Merrill JT; Pacheco-Tena C; Pei J; Nasmyth-Miller C; Pope JE
J Rheumatol; 2018 Apr; 45(4):456-464. PubMed ID: 29247149
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
Ogata A; Kato Y; Higa S; Maeda K
Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
[TBL] [Abstract][Full Text] [Related]
16. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
18. [Persistent aphthous mouth ulcers associated with tocilizumab: two cases].
Samimi M; Lauferon F; Hüttenberger B; Vaillant L; Goupille P; Machet L
Ann Dermatol Venereol; 2013 Feb; 140(2):120-4. PubMed ID: 23395494
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
20. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
Ogata A; Kato Y; Higa S; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):258-267. PubMed ID: 30427250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
